Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Oxide Monohydrate for Nocturnal Leg Cramps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Signed informed consent before any procedure or assessment is done. Age over 21 years old. Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).~Insured by Clalit Health Services (CHS). Hebrew speaking~Exclusion Criteria:~Pregnancy Currently taking Quinidine or Magnesium additive Renal failure - serum creatinine more than 2 mg/DL or estimated glomerular filtration rate (eGFR) less than 60 ml/min (the worst, ascertained by the participant electronic records in the last 6 months). If the result is near these limits (i.e. serum creatinin 1.5-2) a second analysis will be done near the study enrollment.~Major neurological disease- ALS, MS, Paraplegia or Quadriplegia.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MAGNOX 520® (Type: EXPERIMENTAL): MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
- Similarly looking placebo. (Type: PLACEBO_COMPARATOR): Similarly looking placebo. Oral administration once daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).